17 June 2015
Celtaxsys, Inc., Corporation just released form D for $40.00 million equity financing. This is a new filing. Celtaxsys was able to sell $21.63 million so far. That is 54.07% of the financing round. The total offering amount was $40.00 million. The fundraising form was filled on 2015-06-10. The reason for the financing was: unspecified. The fundraising still has about $18.37 million more and is not closed yet. We have to wait more to see if the offering will be fully taken.
Celtaxsys is based in Georgia. The filler’s business is Biotechnology. The form D was submitted by William P Reddick Chief Financial Officer. The company was incorporated more than five years ago. The filler’s address is: 201 17Th Street, Suite 530, Atlanta, Ga, Georgia, 30363. Greg Duncan is the related person in the form and it has address: 201 17Th Street, Suite 530, Atlanta, Ga, Georgia, 30363. Link to Celtaxsys Filing: 000133438115000002.
On average, startups in the Biotechnology sector, sell 73.77% of the total offering size. Celtaxsys sold 54.07% of the offering. The financing is still open. The average investment floor size for companies in the Biotechnology industry is $3.08 million. The total amount raised is 602.24% bigger than the average for companies in the Biotechnology sector. The minimum investment for this offering was set at $0. If you know more about the reasons for the financing, please comment below.
Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.
The Form D signed by William P Reddick might help Celtaxsys, Inc.’s business. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.
PrintMerry Christmas and Happy New Year!
28 December 2024
NovaMedica team in the TOP 100 INFLUENTIAL PEOPLE IN THE PHARMACEUTICAL BUSINESS 2024
28 November 2024
05 November 2024
Enhancing spectroscopy analysis with machine learning
03 February 2025
The production of new Russian “super antibiotic” to begin in Novosibirsk
03 February 2025
A Russian company has started producing 4 veterinary vaccines
31 January 2025
The government held its first meeting on the “New technologies for preserving health” project
31 January 2025